(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 29 July 2004 (29.07.2004)

(10) International Publication Number WO 2004/062673 A1

- (51) International Patent Classification7: 47/10, 47/18, 47/32, 9/08, A61P 33/02
- A61K 31/53,
- (21) International Application Number:

PCT/EP2004/000147

- (22) International Filing Date: 9 January 2004 (09.01.2004)
- (25) Filing Language:

English

(26) Publication Language:

English

- (30) Priority Data: PCT/EP03/00398 16 January 2003 (16.01.2003)
- (71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhouseweg 30, B-2340 Beerse (BE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): DE SPIEGELEER, Bart [BE/BE]; Keizer Karelstraat 228, B-9000 Gent (BE). DOSOGNE, Hilde [BE/BE]; Kapelaanwegel 8. B-9080 Lochristi (BE).
- (74) Common Representative: JANSSEN PHARMACEU-TICA N.V.; Turnhoutseweg 30, B-2340 Beerse (BE).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PII, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ. CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS. JP. KE, KG, KP. KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA. MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO. RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG. ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE. DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD. TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendmenis

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTI-PROTOZOAL COMPOSITIONS COMPRISING DICLAZURIL

(57) Abstract: The present invention relates to compositions suitable for oral, transdermal or parenteral (e.g. intranasal, intramuscular, subcutaneous or intravenous) administration, wherein the composition is comprised of at least one anti-protozoal agent dissolved in a mixture of an alcohol based solvent-system, an emulsifier-system and a base-system. Also provided is a method for prepraring said anti-protozoal compositions and their use in the treatment or prevention of protozoal infections in warm-blooded animals, including humans.